Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjectsBritish Journal of Clinical Pharmacology, 2013
- Novel evidence‐based colchicine dose‐reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P‐glycoprotein inhibitorsArthritis & Rheumatism, 2011
- Clinical Pharmacokinetics of Therapeutic Monoclonal AntibodiesClinical Pharmacokinetics, 2010
- Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1Xenobiotica, 2010
- Pharmacogenetics of β‐BlockersPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2007
- Clinical Pharmacokinetics of RanolazineClinical Pharmacokinetics, 2006
- Population Pharmacokinetics of Olmesartan Following Oral Administration of its Prodrug, Olmesartan MedoxomilClinical Pharmacokinetics, 2005
- Interactions Between Antiretroviral Drugs and Drugs Used for the Therapy of the Metabolic Complications Encountered During HIV InfectionClinical Pharmacokinetics, 2002
- Clinical Pharmacokinetics of CandesartanClinical Pharmacokinetics, 2002
- Pharmacokinetic interactions between sildenafil and saquinavir/ritonavirBritish Journal of Clinical Pharmacology, 2000